By Nick Taylor
The FDA has posted draft guidance to prepare for a GDUFA-driven surge in data on the generic drug supply chain. And it is a familiar scenario, with the FDA drawing heavily on the 2009 electronic drug registration and listing guidance.
Read more: here.
No comments:
Post a Comment